No Data
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $70
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Announces Target Price $70
Earnings Preview: WGS to Report Financial Results Pre-market on October 29
The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts
Express News | Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $54
Mars Mooo OP :